Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034579 · ClinicalTrials.gov registry record · Phase 4
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
A Phase 4 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 4
- Development phase
- 324
- Enrollment target
NCT01034579 is a Phase 4 study that has completed, run by EMD Serono. The registered enrollment target is 324 participants.
The verdict
NCT01034579, a Phase 4 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 324 participants
- Enrollment target
Study Summary
This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial. The aim of this trial is to provide additional data on the factors influencing interferon (IFN) beta response. This is a Phase 4 trial involving subjects who previously participated in the REGARD trial. To address the trial objectives, a single visit follow-up trial will be performed during which a blood sample will be collected.
Interventions
- OTHER Blood sampling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01034579
The ClinicalTrials.gov registry entry for NCT01034579 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood sampling is the first listed.
NCT01034579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01034579 about?
NCT01034579 is a clinical study titled "The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial". This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial. The aim of this trial is to provide additional data on the factors influencing interferon (IFN) b...
What is the current status of trial NCT01034579?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 324 participants. The study started on 2010-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01034579?
The interventions under investigation include: Blood sampling (OTHER).
Who is sponsoring clinical trial NCT01034579?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.